CN115052626A - 用于治疗乙型肝炎感染的干扰素相关抗原结合蛋白 - Google Patents

用于治疗乙型肝炎感染的干扰素相关抗原结合蛋白 Download PDF

Info

Publication number
CN115052626A
CN115052626A CN202080095495.4A CN202080095495A CN115052626A CN 115052626 A CN115052626 A CN 115052626A CN 202080095495 A CN202080095495 A CN 202080095495A CN 115052626 A CN115052626 A CN 115052626A
Authority
CN
China
Prior art keywords
seq
interferon
ifn
antigen binding
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095495.4A
Other languages
English (en)
Chinese (zh)
Inventor
安托万·阿拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evertec International Co ltd
Sanofi Aventis France
Original Assignee
Evertec International Co ltd
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evertec International Co ltd, Sanofi Aventis France filed Critical Evertec International Co ltd
Publication of CN115052626A publication Critical patent/CN115052626A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080095495.4A 2019-12-03 2020-11-27 用于治疗乙型肝炎感染的干扰素相关抗原结合蛋白 Pending CN115052626A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19306551.3 2019-12-03
EP19306551 2019-12-03
EP19306572.9 2019-12-04
EP19306572 2019-12-04
PCT/EP2020/083737 WO2021110561A1 (en) 2019-12-03 2020-11-27 Interferon-associated antigen binding proteins for use in treating hepatitis b infection

Publications (1)

Publication Number Publication Date
CN115052626A true CN115052626A (zh) 2022-09-13

Family

ID=73554457

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095495.4A Pending CN115052626A (zh) 2019-12-03 2020-11-27 用于治疗乙型肝炎感染的干扰素相关抗原结合蛋白

Country Status (10)

Country Link
US (1) US20230028476A1 (https=)
EP (1) EP4069290A1 (https=)
JP (1) JP2023505169A (https=)
KR (1) KR20220109435A (https=)
CN (1) CN115052626A (https=)
AU (1) AU2020397416A1 (https=)
BR (1) BR112022010425A2 (https=)
CA (1) CA3163356A1 (https=)
IL (1) IL293449A (https=)
WO (1) WO2021110561A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
EP4351732A1 (en) * 2021-06-09 2024-04-17 Evotec International GmbH Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
WO2024126294A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126293A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126289A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024213635A1 (en) * 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130266565A1 (en) * 2010-08-05 2013-10-10 F. Hoffmann-La Roche Ag Anti-mhc antibody anti viral cytokine fusion protein
CN104357469A (zh) * 2006-05-03 2015-02-18 科罗拉多州立大学董事会 Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其用途
CN109071655A (zh) * 2016-03-04 2018-12-21 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
CN109414496A (zh) * 2016-04-06 2019-03-01 华盛顿大学 用于乙型肝炎病毒（hbv）的使用hbv核心抗原的治疗性疫苗

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
WO2018087345A1 (en) * 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
JP7676150B2 (ja) * 2018-06-01 2025-05-14 サノフイ Ｂ型肝炎ウイルス感染を治療するための併用療法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104357469A (zh) * 2006-05-03 2015-02-18 科罗拉多州立大学董事会 Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其用途
US20130266565A1 (en) * 2010-08-05 2013-10-10 F. Hoffmann-La Roche Ag Anti-mhc antibody anti viral cytokine fusion protein
CN109071655A (zh) * 2016-03-04 2018-12-21 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
CN109414496A (zh) * 2016-04-06 2019-03-01 华盛顿大学 用于乙型肝炎病毒（hbv）的使用hbv核心抗原的治疗性疫苗

Also Published As

Publication number Publication date
AU2020397416A1 (en) 2022-07-14
KR20220109435A (ko) 2022-08-04
EP4069290A1 (en) 2022-10-12
CA3163356A1 (en) 2021-06-10
JP2023505169A (ja) 2023-02-08
WO2021110561A1 (en) 2021-06-10
BR112022010425A2 (pt) 2022-08-23
IL293449A (en) 2022-07-01
US20230028476A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
CN115052626A (zh) 用于治疗乙型肝炎感染的干扰素相关抗原结合蛋白
JP2019088290A (ja) Ａｓｇｐｒ抗体およびその使用
US12275796B2 (en) Interferon-associated antigen binding proteins and uses thereof
US12162947B2 (en) Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection
AU2020336980B2 (en) Antibody compositions and methods for treating hepatitis B virus infection
JP7404343B2 (ja) 融合タンパク質、並びに腫瘍及び／又はウイルス感染の治療薬を製造するためのその使用
WO2022258720A9 (en) Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
CN112912098A (zh) 用于治疗乙型肝炎病毒感染的组合疗法
CN113544152B (zh) Flt3激动剂抗体及其用途
EA047752B1 (ru) Интерферон-ассоциированные антигенсвязывающие белки и их применение
EA046818B1 (ru) Интерферон-ассоциированные антигенсвязывающие белки для лечения инфекции, вызванной вирусом гепатита в
WO2024213635A1 (en) Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
WO2024126289A1 (en) Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024126293A1 (en) Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
CN121311247A (zh) 特异性结合masp3的抗体以及特异性结合masp3和masp2的多特异性抗体
CN117042797A (zh) 用于治疗乙型肝炎病毒感染的组合物和方法
HK40073510B (zh) 用於治疗乙型肝炎病毒感染的抗体组合物和方法
HK40073510A (en) Antibody compositions and methods for treating hepatitis b virus infection
HK40044100A (en) Fusion protein and its application in preparing medicine for treating tumor and/or viral infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220913